Incyte Corporation — FY2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. This is an annual filing, not a standalone fourth-quarter filing; quarterly figures are noted where relevant. Incyte is a biopharmaceutical company focused primarily on oncology. Its marketed product, JAKAFI (ruxolitinib), was approved in the U.S. for myelofibrosis and, in December 2014, for certain patients with polycythemia vera (PV). Novartis commercializes ruxolitinib outside the U.S. as JAKAVI.
Financial results and liquidity
| Metric | FY2014 | FY2013 | Change / context |
|---|---|---|---|
| Total revenue | $511.5 million | $354.9 million | Up 44% |
| JAKAFI net product revenue | $357.6 million | $235.4 million | Up 52%; management attributed the $122.1 million increase to $92.3 million volume and $29.9 million price |
| JAKAVI royalty revenue | $49.0 million | $28.3 million | Up 73% |
| Contract revenue | $104.9 million | $91.0 million | Included $92.0 million in Novartis milestones, versus $25.0 million in 2013 |
| Research and development | $347.5 million | $260.4 million | Up 33% |
| Selling, general and administrative | $165.8 million | $110.0 million | Up 51% |
| Operating loss | $4.8 million | $16.1 million | Narrower loss |
| Net loss | $48.5 million | $83.1 million | Loss per share was $0.29 versus $0.56 |
| Operating cash flow | $26.3 million provided | $9.2 million provided | Improved by $17.1 million |
Product revenue less reported cost of product revenue was approximately $354.6 million; however, the reported cost was unusually low in part because previously expensed pre-approval inventory remained in use. The company began paying Novartis low-single-digit royalties on U.S. JAKAFI sales in October 2014 and expected product costs to rise to the mid-single digits as a percentage of net product sales after the remaining pre-launch inventory was consumed.
Fourth-quarter 2014 revenue was $124.0 million and net loss was $36.9 million. JAKAFI product revenue was $106.0 million and JAKAVI royalties were $14.7 million in the quarter. In contrast, third-quarter net income of $59.3 million included $88.2 million of contract revenue, principally milestone-related; quarterly results therefore depended materially on the timing of collaboration revenue.
- Cash and liquidity: Cash, cash equivalents and marketable securities totaled $600.3 million at year-end, versus $509.0 million a year earlier. Working capital was $477.7 million; total assets were $830.1 million.
- Cash flows and investment: Operating activities provided $26.3 million; investing activities used $138.4 million, including $27.9 million of capital expenditures and substantial purchases of marketable securities; financing activities provided $93.1 million. Cash and cash equivalents declined $19.1 million, while total cash and marketable securities increased.
- Debt: Aggregate principal debt was $840.9 million, while the balance-sheet carrying amount of convertible notes was $689.1 million. Principal included $90.9 million of 4.75% notes due October 2015, $375.0 million of 0.375% notes due 2018 and $375.0 million of 1.25% notes due 2020. The notes due 2018 and 2020 became convertible for at least the first quarter of 2015; management stated it intended to settle conversions in shares.
- Balance-sheet position: Stockholders’ deficit was $81.6 million; liabilities exceeded assets. The company reported an accumulated deficit of $1.8 billion.
Material changes and business developments
- JAKAFI revenue growth and higher Novartis royalties supported the increase in total revenue. Contract revenue also benefited from $92.0 million in Novartis milestones recognized in 2014, including milestones related to European reimbursement, Japanese approval and capmatinib development.
- R&D increased by $87.1 million, primarily due to higher clinical research and outside-service costs and increased development headcount. Incyte funded $49.3 million of baricitinib rheumatoid-arthritis development costs under its co-development arrangement.
- SG&A rose by $55.8 million, reflecting expanded staffing and commercialization activity for JAKAFI, including preparation for the PV launch.
- Interest expense rose to $46.8 million from $38.7 million, including $35.7 million of non-cash debt-discount amortization. The 2013 comparison included $17.9 million of note-repurchase loss and $11.5 million of debt-exchange expense; those unusual charges were not repeated at similar levels in 2014.
- In December 2014, the FDA approved JAKAFI for PV patients with inadequate response or intolerance to hydroxyurea. In January 2015, the European medicines committee issued a positive opinion for this use of JAKAVI, triggering a $25 million Novartis milestone expected to be recorded in first-quarter 2015.
- In January 2015, Incyte agreed to pay Agenus $25 million upfront for immuno-oncology collaboration rights and $35 million for an equity investment. The planned investment was not reflected in year-end contractual-obligation totals.
Outlook, management commentary and risks
Management gave no specific revenue, earnings or expense guidance. It said existing cash, cash equivalents and marketable securities should fund capital needs for at least the next 12 months, while also expecting continued substantial research and development investment and acknowledging that losses could continue. Future funding needs depend on JAKAFI commercialization, clinical development spending, milestones and other factors; additional financing may be required, with no assurance it will be available on acceptable terms.
- Pipeline: Phase III ruxolitinib trials in pancreatic cancer were ongoing under an FDA Special Protocol Assessment, with enrollment focused on patients with elevated C-reactive protein. Earlier Phase II data showed a survival signal in a prespecified subgroup (hazard ratio 0.47); the filing cautions that an SPA does not guarantee approval. Baricitinib’s first reported Phase III rheumatoid-arthritis study met its primary endpoint; results from three other Phase III studies were expected in 2015.
- Commercial and reimbursement exposure: The company depends heavily on JAKAFI and on continued adoption, adequate reimbursement and pricing, and access to specialty-pharmacy distribution. Government rebates and chargebacks may increase, including following price increases above inflation.
- Supply concentration: Incyte relies on third parties for manufacturing. At filing, a single manufacturer produced JAKAFI finished product; a second source was being qualified. Some ruxolitinib raw materials came from Chinese suppliers, creating potential supply and trade-related exposure.
- Development and regulatory uncertainty: Most pipeline compounds remained investigational and could fail, be delayed or require additional trials. Clinical safety, efficacy, regulatory decisions and collaborator execution are uncertain; several programs depend on Novartis or Lilly.
- Leverage and other risks: The $90.9 million principal maturity in 2015, substantial total debt, interest obligations, negative stockholders’ equity and potential share dilution from convertible notes are important considerations. Other disclosed risks include patent challenges, competition, healthcare regulation, product liability and foreign-exchange effects on royalties.
Ernst & Young issued an unqualified opinion on the financial statements and concluded internal control over financial reporting was effective as of December 31, 2014. The filing reported no legal proceedings.
Important facts for investors to verify
- Whether JAKAFI’s expanded PV indication drives durable sales growth and whether payer coverage, rebates and net pricing support expectations.
- How much future revenue depends on collaboration milestones versus recurring product sales and royalties, and how milestone timing affects quarterly earnings.
- Progress and outcomes for the JANUS pancreatic-cancer trials, the remaining baricitinib Phase III trials, and other priority pipeline studies.
- Repayment or conversion plans for the $90.9 million 2015 notes and the potential dilution and settlement implications of the 2018 and 2020 notes.
- Whether the planned $60 million Agenus collaboration and equity investment closes as expected, and its effect on cash and development spending.
- Manufacturing capacity, qualification of alternate JAKAFI suppliers, and the accuracy of revenue allowances, including government rebates and chargebacks.